Heart failure (HF) is a rapidly growing public health issue with an estimated prevalence of >37.7 million individuals globally. HF is a shared chronic phase of cardiac functional impairment secondary to many aetiologies, and patients with HF experience a range of symptoms that affect their quality of life, including dyspnoea, fatigue, poor exercise tolerance and fluid retention.

The burden of HF will continue to rise, due to population aging, population growth and improved treatment of HF and other cardiovascular disorders. As a result, clinicians will be increasingly challenged to develop treatment plans and care systems that reduce the high levels of morbidity and mortality experienced by these patients, both from their HF and other comorbidities.


Sodium–glucose Cotransporter 2 Inhibitors in Heart Failure


30 April 2019


European Cardiology Review 2019;14(1):23-32

Erratum to: The Inhibitory Effects of Crucumin Glucuronide on p300-HAT Activity and Hypertrophic Phenylephrine- Induced Responses in Cardiomyocytes


European Cardiology Review 2018;13(2):136.

Left Ventricular Ejection Fraction in Heart Failure


European Cardiology Review 2018;13(2):91–2.



European Cardiology Review 2018;13(2):90.